Sugi Predict

Sugi Predict / Compounds / SCHEMBL2946709

SCHEMBL2946709

SCHEMBL2946709

CCC(=O)N[C@H](C(=O)O)C(C)C

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ PLA2G2A P14555 1/20 0.49
▸ PLA2G5 P39877 1/20 0.49
▸ SDCBP O00560 3/20 0.46
▸ SDC2 P34741 3/20 0.46
▸ CYP2C9 P11712 1/20 0.45
▸ TP53 P04637 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ MBTPS1 Q14703 1/20 0.43
▸ EPHX2 P34913 1/20 0.41
▸ FNTA P49354 1/20 0.41
▸ FNTB P49356 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10076074 1.00 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL4182518 1.00 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL22128039 0.85 CYP2C9 (0.41) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL22128037 0.85 CYP2C9 (0.41) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL30569794 0.85 PSMB5 (0.49) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL4195957 0.84 CYP2C9 (0.43) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL4195960 0.84 CYP2C9 (0.43) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL4186736 0.83 ALDH1A1 (0.63) ALDH1A1CYP2C9
SCHEMBL4186738 0.83 ALDH1A1 (0.63) ALDH1A1CYP2C9
SCHEMBL1734627 0.83 PLA2G2A (0.54) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186853-A1 COMPOSITIONS COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF YU RUEY J 2009-07-23 — — US claimed
EP-1865953-A4 COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF YU RUEY J (US) 2008-04-30 — — EP claimed
EP-1865953-A2 COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF Yu, Ruey J., Dr. (US) 2007-12-19 — — EP claimed
WO-2006101940-A2 COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF YU, RUEY, J. (US) 2006-09-28 — — WO claimed
US-20060211754-A1 Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof YU RUEY J 2006-09-21 — — US claimed
US-20050171194-A1 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions YU RUEY J (US) 2005-08-04 — — US claimed
WO-2005055947-A2 ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS YU RUEY J (US) 2005-06-23 — — WO claimed
CN-119192121-A Human cathepsin S inhibitor and application thereof 北京谱峰源生物科技有限公司 2024-12-27 — — CN disclosed
US-20240208895-A1 BRANCHED-CHAIN AMINO ACID DERIVATIVES TO TREAT DISEASE Intrabio Ltd. (GB) 2024-06-27 — — US disclosed
US-20230173093-A1 CHARGE VARIANT LINKERS SEAGEN INC (US) 2023-06-08 — — US disclosed
US-11629171-B2 Beta-hairpin peptidomimetics SPEXIS AG (CH) 2023-04-18 — — US disclosed
CN-115955980-A Variable charge joint 思进公司 2023-04-11 — — CN disclosed
EP-4132588-A1 CHARGE VARIANT LINKERS Seagen Inc. (US) 2023-02-15 — — EP disclosed
WO-2006101940-A2 COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF YU, RUEY, J. (US) 2006-09-28 — — WO disclosed
US-20060211754-A1 Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof YU RUEY J 2006-09-21 — — US disclosed
US-20050171194-A1 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions YU RUEY J (US) 2005-08-04 — — US disclosed
WO-2005055947-A2 ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS YU RUEY J (US) 2005-06-23 — — WO disclosed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 — — EP disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 — — US disclosed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230173093-A1 CHARGE VARIANT LINKERS SSB, UACA, CDA ALDH1A1 1439/4885SMN1; SMN2 2209/4885NPSR1 3705/4885
US-11629171-B2 Beta-hairpin peptidomimetics POLL, POLQ, HBZ ALDH1A1 2445/4885SMN1; SMN2 4075/4885NPSR1 2029/4885
US-20240208895-A1 BRANCHED-CHAIN AMINO ACID DERIVATIVES TO TREAT DISEASE CTSA, GBA1, GAA ALDH1A1 2303/4885SMN1; SMN2 13/4885NPSR1 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.